AHRI and BGI Genomics Sign MoU to Enhance Public Health Outcomes in Ethiopia
On October 13, 2023, in Addis Ababa, Armauer Hansen Research Institute (AHRI) and BGI Genomics signed a Memorandum of Understanding to enhance the Institute's genomics and precision medicine capabilities.
Dr. Ning Li, Deputy General Manager, BGI Genomics, and Professor Afework Kassu, Director, Armauer Hansen Research Institute. Source: AHRI
The Institute got its name from the Norwegian physician, Gerhard Henrik Armauer Hansen, who first described the leprosy bacillus (Mycobacterium leprae) and joined the Ethiopian Ministry of Health in 2004. Located in Addis Ababa, it serves as a biomedical hub for the region.
BGI Genomics provides precision medicine solutions in more than 100 countries worldwide. Leveraging the company’s latest technologies, this agreement will foster cooperation with AHRI on research and development to enhance health outcomes in Ethiopia and Africa.
Professor Afework Kassu, the Director of the Institute, said AHRI aims to be a leading center in genomics and bioinformatics, which will serve not only Ethiopia but also neighboring countries in Africa. This agreement also showcases the growing cooperation between Ethiopia and China companies.
BGI Genomics and AHRI Teams. Source: AHRI
About BGI Genomics:
BGI Genomics, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange
NIFTY® DNBSEQ-G99 Platform Achieves CE-IVDD Certification - Enhancing Prenatal Care Options
World Cancer Day 2024: Close the Care Gap through Awareness, Early Detection, and Universal Access l BGI Perspectives